BIOVENTIX PLC Logo

BIOVENTIX PLC

Develops high-affinity sheep monoclonal antibodies for global clinical diagnostic immunoassays.

BVXP | IL

Overview

Corporate Details

ISIN(s):
GB00B4QVDF07
LEI:
213800225MHX7LZQY108
Country:
United Kingdom
Address:
7 ROMANS BUSINESS PARK, GU9 7SX FARNHAM
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Bioventix PLC is a biotechnology company specializing in the development and commercial supply of high-affinity sheep monoclonal antibodies (SMAs). These antibodies are utilized as critical components in clinical diagnostic applications, primarily for automated immunoassays used in blood testing. The company supports healthcare organizations by creating novel SMAs, with a development timeline of approximately nine months from initial immunisation to the delivery of purified antibodies for evaluation. Its product portfolio includes a range of SMAs for the global clinical diagnostics market and ELISA kits designed to monitor exposure to industrial pollutants. The company's antibodies are instrumental in various diagnostic areas, including troponin assays for assessing cardiac conditions and research into neurological disorders like Alzheimer's disease.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-30 08:00
Director's Dealing
Director Dealing
English 19.2 KB
2025-10-27 16:53
Director's Dealing
Director Dealing
English 19.1 KB
2025-08-13 15:19
Major Shareholding Notification
Holding(s) in Company
English 22.0 KB
2025-04-28 18:13
Director's Dealing
Director Dealing
English 19.8 KB
2025-03-31 08:00
Interim Report
Interim Results
English 106.1 KB
2024-12-24 10:14
Director's Dealing
Director Dealing
English 19.3 KB
2024-12-06 08:00
Post-Annual General Meeting Information
Result of AGM
English 8.1 KB
2024-12-04 16:34
Major Shareholding Notification
Holding(s) in Company
English 52.9 KB
2024-11-22 16:56
Director's Dealing
Director/PDMR Shareholding
English 19.5 KB
2024-11-08 08:57
Report Publication Announcement
Notice of AGM
English 8.1 KB
2024-10-31 08:00
Director's Dealing
Director/PDMR Shareholding
English 19.2 KB
2024-10-28 08:00
Annual / Quarterly Financial Statement
Results for the year ended 30 June 2024
English 442.9 KB
2024-10-25 11:37
Major Shareholding Notification
Holding(s) in Company
English 31.1 KB
2024-10-16 14:51
Major Shareholding Notification
Holding(s) in Company
English 43.9 KB
2024-04-30 08:00
Director's Dealing
Director/PDMR Shareholding
English 19.2 KB

Automate Your Workflow. Get a real-time feed of all BIOVENTIX PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BIOVENTIX PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BIOVENTIX PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
CDT Equity Inc. Logo
Clinical-stage biopharma using AI to enhance and advance therapies for unmet medical needs.
United States of America CDT
CELADON PHARMACEUTICALS PLC Logo
Vertically integrated pharma developing cannabis medicines for chronic pain.
United Kingdom CEL
Celcuity Inc. Logo
Developing targeted PI3K/mTOR inhibitor therapies for breast and prostate solid tumors.
United States of America CELC
Celemics, Inc. Logo
Develops custom NGS panels and bioinformatics for research and clinical diagnostics.
South Korea 331920
Develops & manufactures radiopharmaceuticals for cancer diagnosis and therapy.
South Korea 308430
CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea 049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
United States of America CLDX
Cellectar Biosciences, Inc. Logo
Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.
United States of America CLRB
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France ALCLS
Cellectis S.A. Logo
Developing allogeneic CAR T-cell cancer immunotherapies using TALEN® gene-editing technology.
United States of America CLLS

Talk to a Data Expert

Have a question? We'll get back to you promptly.